XEN496

Phase 3Small molecule

XEN496 is one of 4 small molecule programs targeting Developmental and Epileptic Encephalopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Developmental and Epileptic EncephalopathyActive, not recruiting

Developmental and Epileptic EncephalopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Developmental and Epileptic Encephalopathy

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Approved

—2

LP352

LLongboard Pharmaceuticals

Phase 3

1 3

XEN496

XXenon Pharmaceuticals Inc.

Phase 3

1 4

NBI-921352

Neurocrine Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Developmental and Epileptic Encephalopathy1 trial

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Terminated·XXenon Pharmaceuticals Inc.·Phase 3·NCT04639310·8 enrolled

Children1 trial

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Terminated·XXenon Pharmaceuticals Inc.·Phase 3·NCT04912856·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for XEN496. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XEN496 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XEN496. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xenon Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXenon Pharmaceuticals Inc.

XEN496

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Developmental and Epileptic Encephalopathy1 trial

Children1 trial

References

Drug Info

Quick Facts

Related News